2013 Public Outcomes Report

STANDARD 4.6: MONITORING COMPLIANCE WITH EVIDENCE-BASE GUIDELINES TEN PERCENT RANDOM REVIEW OF THE ANNUAL ANALYTIC CASELOAD

Charts were randomly selected from the 93 analytic cases in 2012, with an attempt to capture at least one case from each of the major diagnosis sites. The following list indicates the disease sites that were audited and how many charts in each category.

- Breast (2)
- Colon (1)
- Lung (1)
- Prostate (1)
- Pancreas (1)
- Blood & Bone Marrow (1)
- Skin (1)
- Corpus Uteri (1)
- Lymph Nodes (1)

EACH CASE WAS AUDITED FOR THE FOLLOWING:

- American Joint Committee on Cancer (AJCC) staging (clinical and pathologic, when appropriate)
- compliance with National Comprehensive Cancer Network (NCCN)
 Guidelines
- select prognostic indicators for each site.

THE FOLLOWING AUDIT SHEETS WERE THE WORKING TOOLS FOR THIS STUDY.

SUMMARY REPORT OF MEDICAL RECORD AUDIT FOR 2012 CASES

Total number of charts reviewed: 10

Total number of analytic cases: 93

Percent of cases reviewed: 10.7%



BREAST CANCER (N=2)

Treatment Summary

- 2 of 2 patients initial treatment included a lumpectomy with sentinel lymph node biopsy
- 1 of 2 patients sentinel lymph node biopsy converted to axillary lymph node dissection due to a positive sentinel node
- 1 of 2 patients received adjuvant chemotherapy
- 2 of 2 patients received adjuvant radiation
- 1 of 2 patients eventually had a bilateral mastectomy for multifocal disease
- 1 of 2 patients Her2 positive and received Herceptin
- 2 of 2 patient received hormonal treatment

Staging and NCCN Guideline Compliance

- 2 of 2 patients had a clinical stage documented
- Staging workup and treatment were compliant with NCCN Guidelines for both patients

Prognostic Indicators

• Tumor grade, ER status, PR status and Her2 Status are documented on all patients diagnosed in the Allina Health system

COLON (N=1)

Treatment Summary

- 1 of 1 patient was treated with surgery
- 1 of 1 patient received adjuvant chemotherapy

Staging and NCCN Guideline Compliance

- 1 of 1 patient had a clinical stage documented
- Staging workup was completed and treatment was compliant with NCCN Guidelines

Prognostic Indicators

 All prognostic indicators were documented on the audited case

LUNG (N=1)

Treatment Summary

- 1 of 1 patient was treated with chemotherapy
- 1 of 1 patient was treated with stereotactic radiation to the metastatic brain disease

Staging and NCCN Guideline Compliance

- Clinical stage was documented in the audited case
- Staging workup was completed and treatment was compliant with NCCN Guidelines

Prognostic Indicators

 All prognostic indicators were documented and reviewed in the audited case

PROSTATE (N=1)

Treatment Summary

- 1 of 1 patient was treated with hormonal treatment
- 1 of 1 patient was treated with chemotherapy

- 0 of 1 patient was eligible for surgery due to the stage of the disease
- 0 of 1 patient was eligible for radiation due to the stage of the disease

Staging and NCCN Guideline Compliance

- Clinical stage was documented in the audited case
- Staging workup was completed and treatment was compliant with NCCN Guidelines

Prognostic Indicators

• All audited prognostic indicators were documented in the audited case

PANCREAS (N=1)

Treatment Summary

• 1/1 patient opted for hospice care only

Staging and NCCN Guideline Compliance

- Clinical stage was documented
- Staging workup was not completed due to the patient's condition and wished to proceed directly to hospice care

BLOOD AND BONE MARROW (N=1)

Staging and NCCN Guideline Compliance

• Staging workup was completed and treatment was compliant with NCCN Guidelines

SKIN (N=1)

Staging and NCCN Guideline Compliance

• Staging workup was completed and treatment was compliant with NCCN Guidelines

Prognostic Indicators

• Measured thickness, mitotic rate and ulceration are documented on all patients diagnosed in the Allina Health system

UTERINE (N=1)

Staging and NCCN Guideline Compliance

• Staging workup was completed and treatment was compliant with NCCN Guidelines

Prognostic Indicators

• FIGO stage, peritoneal cytology and omenectomy results were documented on the audited case

LYMPH NODES (N=1)

Staging and NCCN Guideline Compliance

• Staging workup was completed and treatment was compliant with NCCN Guidelines

Prognostic Indicators

• B-symptoms were documented on the audited case

		Standa	ord 4.6 Monitori	ng Compliand	e with Evide	nce-Based Gu	idelines			
	Compliance	with AJCC Sta	aging and NCCN	l Guidelines	Prognostic Indicators					
Breast	Treatment Modality appropriate for stage? (Y/N)	Clinically Staged (Y/N)	Pathological Stage in Path Report (Y/N)	NCCN Guidelines Met (Y/N)	Tumor Grade (I/ II/III)	ER Status (+/-)	PR Status (+/-)	Her2 Status (+/-)	N/A	
Case #1	Yes	Yes	Yes	Yes	I	+	+	-		
Case #2	Yes	Yes	Yes	Yes	III	+ (35%)	-	+		
	Compl	iance with A	JCC Staging an	d NCCN Guid	elines	Prognostic Indicators				
Colon	Clinically Staged (Y/N)	Staging work up completed (Y/N)	Treatment Modality appropriate for stage? (Y/N)	Pathologic Stage in Path Report (Y/N)	NCCN Guidelines Met (Y/N)	Pre- treatment CEA done (Y/N)	# of Regional lymph nodes evaluated	Peri-neural invasion	Tumor Grade	
Case #3	Yes	Yes	Yes	Yes	Yes	Yes (< 0.5)	24	-	2/4	
	Compliance with AJCC Staging and NCCN Guidelines					Prognostic Indicators				
Lung	Clinically Staged (Y/N)	Staging work up completed (Y/N)	Treatment Modality appropriate for stage? (Y/N)	Pathologic stage? (Y/N)	NCCN Guidelines Met (Y/N)	Histology documented	Age at Diagnosis	Sex (male/ female)	N/A	
Case #4	Yes	Yes	Yes	Yes	Yes	Yes (Large Cell, Neuro- endocrine)	75	male		
	Compl	iance with A	JCC Staging an	Prognostic Indicators						
Prostate	Clinically Staged (Y/N)	Staging work up completed (Y/N)	Treatment modality appropriate for stage? (Y/N)	Pathologic stage?	NCCN Guidelines Met (Y/N)	PSA	Gleason Score	# biopsy cores positive/# of biopsy cores examined	N/A	
Case #5	Yes	Yes	Yes	Yes	Yes	175.3	9	10/12		
	Complian	ce with AJ(CC Staging a	nd NCCN G	Prognostic Indicators					
Pancreas	Clinically Staged (Y/N)	Staging work up completed	Treatment sequence	Pathologic stage?	NCCN Guidelines Met (Y/N)	N/A	N/A	N/A	N/A	
Case #6	Yes	Yes	Hospice	Yes	Yes					

		Standa	ard 4.6 Monitor	ing Compliand	ce with Evide	nce-Based Gu	iidelines		
	Compliance	with AJCC Sta	aging and NCCI	N Guidelines	Prognostic Indicators				
Blood and Bone Marrow	Diagnostic Workup complete	NCCN Guidelines Followed	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Case #7	Yes	Yes							
	Compliance	with AJCC Sta	aging and NCCI	N Guidelines	Prognostic Indicators				
Skin	Diagnostic Workup complete	NCCN Guidelines Followed	N/A	N/A	Measured Thickness	Ulceration	Mitotic Rate	N/A	N/A
Case #8	Yes	Yes			0.20 mm	Not identified	No mitotic figures identified		
	Compliance with AJCC Staging and NCCN Guidelines				Prognostic Indicators				
	Compliance	with AJCC Sta	aging and NCCI	N Guidelines		Prog	gnostic Indica	tors	
Uterine	Diagnostic Workup complete	NCCN Guidelines Followed	aging and NCCI N/A	N Guidelines N/A	FIGO Stage	Peritoneal Cytology Results	Omen- ectomy Performed (Y/N)	tors N/A	N/A
Uterine Case #9	Diagnostic Workup	NCCN Guidelines			FIGO Stage	Peritoneal Cytology	Omen- ectomy Performed		N/A
	Diagnostic Workup complete Yes	NCCN Guidelines Followed Yes		N/A	, and the second	Peritoneal Cytology Results negative	Omen- ectomy Performed (Y/N)	N/A	N/A
	Diagnostic Workup complete Yes	NCCN Guidelines Followed Yes	N/A	N/A	, and the second	Peritoneal Cytology Results negative	Omen- ectomy Performed (Y/N)	N/A	N/A